Although tumors showed sustained YAP, Cyr61, and CTGF loss, they were still able to eventually grow to the IACUC-defined tumor burden, suggesting that RMS cells have mechanisms to overcome YAP inhibition, and this may be due to the activity of oncogenic Ras or other compensatory pathways. This evidence concerns the gene CCN2 and neoplasm.